Candel Therapeutics (CADL) Cash from Operations (2020 - 2025)

Candel Therapeutics' Cash from Operations history spans 4 years, with the latest figure at 7422000.0 for Q4 2023.

  • On a quarterly basis, Cash from Operations fell 7.8% to 7422000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 34244000.0, a 8.99% decrease, with the full-year FY2025 number at 38311000.0, down 41.77% from a year prior.
  • Cash from Operations hit 7422000.0 in Q4 2023 for Candel Therapeutics, up from 8808000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CADL hit a ceiling of 1505000.0 in Q3 2020 and a floor of 10819000.0 in Q1 2023.
  • Historically, Cash from Operations has averaged 6628714.29 across 4 years, with a median of 6995500.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 358.07% in 2021 and later grew 6.14% in 2023.
  • Tracing CADL's Cash from Operations over 4 years: stood at 3416000.0 in 2020, then plummeted by 53.34% to 5238000.0 in 2021, then tumbled by 31.44% to 6885000.0 in 2022, then decreased by 7.8% to 7422000.0 in 2023.
  • Business Quant data shows Cash from Operations for CADL at 7422000.0 in Q4 2023, 8808000.0 in Q3 2023, and 7195000.0 in Q2 2023.